Ascendis Pharma AS (ASND)
122.64
-1.74
(-1.40%)
USD |
NASDAQ |
Nov 21, 16:00
122.73
+0.09
(+0.07%)
After-Hours: 20:00
Ascendis Pharma Revenue (Quarterly): 63.61M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 63.61M |
| June 30, 2024 | 38.76M |
| March 31, 2024 | 104.16M |
| December 31, 2023 | 148.29M |
| September 30, 2023 | 52.30M |
| June 30, 2023 | 51.68M |
| March 31, 2023 | 36.08M |
| December 31, 2022 | 23.41M |
| September 30, 2022 | 15.40M |
| June 30, 2022 | 6.562M |
| March 31, 2022 | 7.662M |
| December 31, 2021 | 5.601M |
| September 30, 2021 | 1.312M |
| June 30, 2021 | 1.232M |
| March 31, 2021 | 0.8989M |
| December 31, 2020 | 0.6379M |
| September 30, 2020 | 3.224M |
| June 30, 2020 | 1.582M |
| March 31, 2020 | 2.455M |
| December 31, 2019 | 2.776M |
| September 30, 2019 | 2.494M |
| June 30, 2019 | 3.607M |
| Date | Value |
|---|---|
| March 31, 2019 | 6.150M |
| December 31, 2018 | 12.00M |
| September 30, 2018 | 0.0233M |
| June 30, 2018 | 0.0215M |
| March 31, 2018 | 0.0344M |
| December 31, 2017 | 0.3297M |
| September 30, 2017 | 0.5102M |
| June 30, 2017 | 0.4885M |
| March 31, 2017 | 0.3963M |
| December 31, 2016 | 1.125M |
| September 30, 2016 | 1.305M |
| June 30, 2016 | 1.283M |
| March 31, 2016 | 1.388M |
| December 31, 2015 | 2.163M |
| September 30, 2015 | 2.353M |
| June 30, 2015 | 2.147M |
| March 31, 2015 | 2.348M |
| December 31, 2014 | 3.529M |
| September 30, 2014 | 4.307M |
| June 30, 2014 | 5.367M |
| March 31, 2014 | 5.472M |
| December 31, 2013 | 7.568M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.6379M
Minimum
Dec 2020
148.29M
Maximum
Dec 2023
28.38M
Average
7.112M
Median
Revenue (Quarterly) Benchmarks
| Novo Nordisk AS | 10.51B |
| Evaxion Biotech AS | 3.017M |
| Trinity Biotech PLC | 15.15M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -109.10M |
| Total Expenses (Quarterly) | 170.00M |
| EPS Diluted (Quarterly) | -1.892 |
| Enterprise Value | 7.615B |
| Gross Profit Margin (Quarterly) | 80.63% |
| Profit Margin (Quarterly) | -171.5% |
| Earnings Yield | -6.60% |
| Normalized Earnings Yield | -6.604 |